Resistance to therapies is one of the obstacles to overcome in cancer treatments. Understanding the mechanisms of this resistance is essential to design strategies that favor tumor cell death. A study led by the Protein Kinases ...
Dec 14, 2023
0
14
Spinal muscular atrophy (SMA) is a devastating pediatric neuromuscular disorder caused by loss-of-function mutations in the SMN1 gene, which prevents the body from producing enough of the survival motor neuron (SMN) protein ...
Dec 7, 2023
0
11
Modulating the activity of a kinase in motor neurons may help mitigate mitochondrial defects and other symptoms of spinal muscular atrophy, offering a new therapeutic avenue for the devastating disease, according to a Northwestern ...
Dec 5, 2023
0
28
Chimeric antigen receptors (CARs) have opened up an exciting new field of therapeutic advancements for rare and difficult-to-treat cancers, as they have the ability to deliver targeted therapies that can kill tumor cells.
Dec 1, 2023
0
30
Biliary tract cancers (BTCs) including cholangiocarcinoma (CCA) and gallbladder cancer (GBC) are becoming more prevalent globally. An effective chemotherapeutic agent for the treatment of BTCs is gemcitabine. Other novel ...
Nov 30, 2023
0
1
Hormone therapy may be associated with menopause and fertility treatment, but now an SDU-led research team reports that certain intestinal hormones seem to have a beneficial effect on the processes behind the formation of ...
Nov 16, 2023
0
6
Neuroscientists at the Faculty of Medicine and Surgery of the Catholic University, Rome, and the Fondazione Policlinico Universitario Agostino Gemelli IRCCS have genetically modified a molecule, the protein LIMK1, which is ...
Nov 15, 2023
0
360
Researchers at MUSC Hollings Cancer Center believe that some drugs already approved by the FDA or currently in clinical trials could be repurposed for certain breast cancer patients whose cancer has become resistant to standard ...
Nov 2, 2023
0
42
A new gene therapy for sickle cell disease has been deemed safe by a U.S. Food and Drug Administration advisory panel, paving the way for full approval by early December 2023.
Nov 2, 2023
0
1
A novel therapeutic approach that combines human epidermal growth receptor factor 2 (HER2)-targeted therapies with the cholesterol-lowering drug lovastatin can reduce the number of cancer treatments required to prevent tumor ...
Oct 12, 2023
0
38
